Contineum Therapeutics Inc CTNM

US Pharmaceuticals

$12.56 ▲ +0.56% (+$0.07)

Open $12.57

Prev Close $12.49

Day Range $12.10 – $12.88

52W Range $8.60 – $17.79

Market Cap $469.89M

Beta 0.07

EPS (TTM) $-1.74

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-04-05
Shares Out.	37,390,000
Website	contineum-tx.com/ ↗
Phone	18583335280
Employees	51
Revenue	$0
Gross Profit	$0
Net Income	-$15.2M
Free Cash Flow	-$53.5M
Total Assets	$250.4M
Total Liabilities	$10.7M
Equity	$239.7M

About Contineum Therapeutics Inc

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics Inc is a publicly traded company under the ticker symbol CTNM on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.